SlideShare a Scribd company logo
1 of 18
Faculty of Pharmacy, BBDNIIT Lucknow
Drug Interaction
Presented by-
Manish Kumar Singh
M.Pharm, I Year (Pharmaceutics)
Presented to-
Ms. Shipra Tripathi
Assistant Professor
Content
 Pharmacokinetic
 Drug interaction
 Factor contributing to drug interactions
 Protein binding of drug
 Effect of protein binding interaction
 Effect of tissue binding interaction
Pharmacokinetics
 Pharmacokinetics is a study of what the
body does to drug.
 It is a science of kinetics of ADME.
 It is also defined as movement of drug
in the body.
 Elimination occur by two processes-
Metabolism and Excretion.
Drug Interactions
 When the pharmacological activity of a drug is altered by the concomitant use of
another drug or by the presence of some other substance.
 The drug whose activity is affected by such an interaction is called as the object
drug.
 The agent which precipitates such an interaction is referred to as the precipitant.
Drug interactions include
1. Drug-drug interactions.
2. Food-drug interactions, for example, inhibition of metabolism of several drugs
by grapefruit juice.
3. Chemical-drug interactions, for example, interaction of a drug with alcohol,
tobacco or environmental chemicals.
4. Drug-laboratory test interaction, for example, alteration of diagnostic laboratory
test results by the presence of drug.
5. Drug-disease interactions, for example, worsening of disease condition by the
drug.
Factors Contributing to Drug
Interactions
Some of the more important risk factors that lead to drug interactions
include –
1. Multiple drug therapy
2. Multiple prescribers
3. Multiple pharmacological effects of drug
4. Multiple diseases/Predisposing illness
5. Poor patient compliance
6. Advancing age of patient
7. Drug related factors
Protein binding of drug
The phenomenon of complex formation with proteins is called as protein
binding of drugs.
The formation of a drug–protein complex is often named drug–protein
binding.
The drug protein binding may be of two types-
Reversible-
When the drug bind the protein with weaker chemical bonds such as hydrogen
bond or vander waal’s forces.
Irreversible-
Irreversible drug protein binding is usually a result of chemical activation of
the drugs, which then attaches strongly to the protein or macromolecules by
covalent chemical bonding.
BINDING OF DRUGS TO BLOOD
COMPONENTS
 Albumin
 Alpha 1- Acid Glycoprotein
 Lipoprotein
 Erythrocytes (RBC)
 Immunoglobulins
The extent or order of binding of drugs to various plasma proteins is:
Abumin > alpha1-Acid Glycoprotein > Lipoproteins > Globulins
Effect of protein binding interactions
Apparent volume of distribution :
It is defined as the hypothetical volume of body fluid into which a drug is dissolved
or distributed. It is called as apparent volume because all parts of the body
equilibrated with the drug do not have equal concentration.
Effect Of Protein Binding On The Apparent Volume Of Distribution :
 The extent of drug protein binding affects VD.
 Drugs that are highly bound to plasma proteins have a low fraction of free drug
(fu = unbound or free drug fraction).
 The plasma protein-bound drug does not diffuse easily and is therefore less
extensively distributed to tissues
Apparent volume of distribution = Amount of the drug in the body
Plasma drug concentration
 Drugs with low plasma protein binding have larger fu, generally diffuse more
easily into tissues, and have a greater volume of distribution.
 Drugs such as furosemide, sulfisoxazole, tolbutamide, and warfarin are bound
greater than 90% to plasma proteins and have a VD value ranging from 7.7 to
11.2 L per 70-kg body weight.
 Basic drugs such as imipramine, nortriptyline, and propranolol are extensively
bound to both tissue and plasma proteins and have very large VD values.
Displacement of drugs from plasma proteins can affect the pharmacokinetics of a
drug in several ways : directly increase the free (unbound) drug concentration as a
result -
1. Reduced binding in the blood;
2. Reaches the receptor sites directly, causing a more intense pharmacodynamic
(or toxic) response;
3. Causing a transient increase in VD and decreasing partly some of the increase
in free plasma drug concentration;
4. More drug diffusion into tissues of eliminating organs, particularly the liver
and kidney, resulting in a transient increase in drug elimination.
Effect Of Protein Binding On Elimination Of Drug :
 Protein binding decreases the renal excretion of the drugs and enhance the
biological half –life. Only the free drugs excreted through filtration for
example tetracycline.
 The binding of drugs in extravascular organs decreases their concentration in
blood and thereby shows their elimination by liver, kidney and lungs.
 However, the binding of drug to plasma protein may retard the elimination of
drugs depending on the mechanism of elimination, for example the binding
of drug to the plasma protein lowers their unbound concentration in blood
and thereby decreases their rate of elimination by glomerular filtration and by
inefficient transport system in the kidney.
 Binding to plasma protein would decreases the rate of elimination of lipid
soluble drugs that diffuse rapidly from the glomerular filtration back into the
blood, even though they are rapidly transported by active transport system.
 In addition, the binding of drug to plasma protein would also decreases the
rate of drug metabolism by relatively inactive enzyme system in liver.
Effect Of Protein Binding On Patient With Kidney Disease :
 Albumin is primarily responsible for the binding of acidic drugs whereas
basic drugs appear to bind preferentially to AAG (alpha-amino glycoprotein).
 The low concentration of albumin and AAG in patients with liver disease
indicates the inability of the liver to synthesize these drug-binding proteins.
 Impaired binding of acidic and basic drugs is well documented in patients
with liver disease.
 The albumin concentrations in the transplant patients were low despite stable
biochemical liver tests. Because albumin is primarily responsible for binding
of acidic drugs, liver transplant patients would not be able to bind acidic
drugs as efficiently as the normal subjects.
 However, the AAG concentrations were elevated in all the transplant patients
studied. AAG is an acute-phase reactant and is primarily synthesized in the
liver.
 AAG concentrations are known to increase in plasma.
Effect Of Protein Binding On Patients With Hepatic Disease :
 Protein binding affects distribution.
 The impaired liver is unable to synthesize plasma proteins (albumin)
adequately.
 Liver impairment causes accumulation of substances (bilirubin) that displace
drugs from protein-binding sites.
 A statistics on this case shows that liver disease patients with normal
concentration of albumin and bilirubin have unbound percentages of
frusemide similar to those in healthy subjects.
Effect of tissue binding interactions
TISSUE BINDING OF DRUGS (TISSUE LOCALIZATION OF DRUGS)
A drug can bind to one or more of the several tissue components. Tissue-drug
binding is important in distribution from two viewpoints :
 It increases the apparent volume of distribution of drugs in contrast to plasma
protein binding which decreases it.
 Tissue-drug binding results in localization of a drug at a specific site in the
body (with a subsequent increase in biological half-life). This is more so
because a number of drugs bind irreversibly with the tissues (contrast to
plasma protein-drug binding); for example, oxidation products of
paracetamol, phenacetin, chloroform, carbon tetrachloride and bromobenzene
bind covalently to hepatic tissues.
Factors influencing localization of drugs in tissues include :
1. lipophilicity and structural features of the drug,
2. perfusion rate,
3. pH differences, etc.
Extensive tissue-drug binding suggests that a tissue can act as the storage site
for drugs. Drugs that bind to both tissue and plasma components result in
competition between drug binding sites.
For majority of drugs that bind to extravascular tissues, the order of binding is:
Liver > Kidney > Lung > Muscles
Several Examples Of Extravascular Tissue-drug Binding Are
1. Liver: Paracetamol bind irreversibly to liver tissues resulting in hepatotoxicity.
2. Lungs: Basic drugs like imipramine, chlorpromazine and antihistamines
accumulate in lungs.
3. Kidneys: Metallothionin, a protein present in kidneys, binds to heavy metals
such as lead, mercury, and cadmium and results in their renal accumulation
and toxicity.
4. Skin: Chloroquine and phenothiazines accumulate in skin by interacting with
melanin.
5. Eyes: The retinal pigments of the eye also contain melanin. Binding of
chloroquine and phenothiazines to it is responsible for retinopathy.
6. Hairs: Arsenicals, chloroquine and phenothiazines are reported to deposit in
hair shafts.
7. Bones: Tetracycline is a well-known example of a drug that binds to bones
and teeth. Administration of this antibiotic to infants or children during
odontogenesis results in permanent brown-yellow discoloration of teeth.
8. Fats: Lipophilic drugs such as thiopental and the pesticide DDT accumulate
in adipose tissues by partitioning into it.
9. Nucleic Acids: Molecular components of cells such as DNA interact
strongly with drugs like chloroquine and quinacrine resulting in distortion of
its double helical structure.
References
 Shargel L. ,” Applied Biopharmaceutics & Pharmacokinetics”, 7th
Edition, 2005, Published by McGraw Hill, New York, Page no –
267,276,277.
 Brahmankar D.M. , Jaiswal S.B. , “Biopharmaceutics and
Pharmacokinetics- A Treatise”, 1995, Published by Vallabh Prakashan,
New Delhi, Page no- 116-123.
 https://www.slideshare.net/azamushahiullahprottoy/effects-of-protein-
binding
Drug interaction

More Related Content

What's hot

Drug product performance , in vivo: bioavailability and bioequivalence
Drug product performance , in vivo: bioavailability and bioequivalenceDrug product performance , in vivo: bioavailability and bioequivalence
Drug product performance , in vivo: bioavailability and bioequivalenceDipakKumarGupta3
 
Computers in Pharmaceutical emulsion development.
Computers in Pharmaceutical emulsion development. Computers in Pharmaceutical emulsion development.
Computers in Pharmaceutical emulsion development. Arpitha Aarushi
 
Clinical significance of be studies
Clinical significance of be studiesClinical significance of be studies
Clinical significance of be studiesDurgadevi Ganesan
 
SCIENTIFICALLY BASED QUALITY BY DESIGN(QBD) and APPLICATION.pptx
SCIENTIFICALLY BASED QUALITY BY DESIGN(QBD) and APPLICATION.pptxSCIENTIFICALLY BASED QUALITY BY DESIGN(QBD) and APPLICATION.pptx
SCIENTIFICALLY BASED QUALITY BY DESIGN(QBD) and APPLICATION.pptxPawanDhamala1
 
Design and evaluation of bioequivalence
Design and evaluation of bioequivalenceDesign and evaluation of bioequivalence
Design and evaluation of bioequivalenceChandrika Mourya
 
Electrosomes preparation and application
Electrosomes preparation and applicationElectrosomes preparation and application
Electrosomes preparation and applicationmahesh745
 
Bioequivalence studies ( Evaluation and Study design)
Bioequivalence studies ( Evaluation and Study design)Bioequivalence studies ( Evaluation and Study design)
Bioequivalence studies ( Evaluation and Study design)Selim Akhtar
 
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...PRAJAKTASAWANT33
 
Computer simulations in pharmacokinetics and pharmacodynamics
Computer simulations in pharmacokinetics and pharmacodynamicsComputer simulations in pharmacokinetics and pharmacodynamics
Computer simulations in pharmacokinetics and pharmacodynamicsGOKULAKRISHNAN S
 
Computers in Pharmaceutical formulation
Computers in Pharmaceutical formulationComputers in Pharmaceutical formulation
Computers in Pharmaceutical formulationsonalsuryawanshi2
 
REGULATORY AND INDUSTRY VIEWS ON QbD, SCIENTIFICALLY BASED QbD- EXAMPLES OF A...
REGULATORY AND INDUSTRY VIEWS ON QbD, SCIENTIFICALLY BASED QbD- EXAMPLES OF A...REGULATORY AND INDUSTRY VIEWS ON QbD, SCIENTIFICALLY BASED QbD- EXAMPLES OF A...
REGULATORY AND INDUSTRY VIEWS ON QbD, SCIENTIFICALLY BASED QbD- EXAMPLES OF A...Ardra Krishna
 
Targeted drug delivery system
Targeted drug delivery systemTargeted drug delivery system
Targeted drug delivery systemIsmailMakanadar
 
alternative methods for dissolution.pptx
alternative methods for dissolution.pptxalternative methods for dissolution.pptx
alternative methods for dissolution.pptxanumalagundam sreekanth
 
Pharmacokinetics and pharmacodynamics of biotechnological products
Pharmacokinetics  and  pharmacodynamics  of  biotechnological  productsPharmacokinetics  and  pharmacodynamics  of  biotechnological  products
Pharmacokinetics and pharmacodynamics of biotechnological productsPV. Viji
 
Problems of variable
Problems of variableProblems of variable
Problems of variableSAKSHI YADAV
 
Compendial methods of dissolution testing
Compendial methods of dissolution testing Compendial methods of dissolution testing
Compendial methods of dissolution testing Nagaraju Ravouru
 
DESCRIPTIVE VERSUS MECHANISTIC MODELING ppt..pptx
DESCRIPTIVE VERSUS MECHANISTIC MODELING ppt..pptxDESCRIPTIVE VERSUS MECHANISTIC MODELING ppt..pptx
DESCRIPTIVE VERSUS MECHANISTIC MODELING ppt..pptxPawanDhamala1
 

What's hot (20)

Drug product performance , in vivo: bioavailability and bioequivalence
Drug product performance , in vivo: bioavailability and bioequivalenceDrug product performance , in vivo: bioavailability and bioequivalence
Drug product performance , in vivo: bioavailability and bioequivalence
 
Computers in Pharmaceutical emulsion development.
Computers in Pharmaceutical emulsion development. Computers in Pharmaceutical emulsion development.
Computers in Pharmaceutical emulsion development.
 
Clinical significance of be studies
Clinical significance of be studiesClinical significance of be studies
Clinical significance of be studies
 
SCIENTIFICALLY BASED QUALITY BY DESIGN(QBD) and APPLICATION.pptx
SCIENTIFICALLY BASED QUALITY BY DESIGN(QBD) and APPLICATION.pptxSCIENTIFICALLY BASED QUALITY BY DESIGN(QBD) and APPLICATION.pptx
SCIENTIFICALLY BASED QUALITY BY DESIGN(QBD) and APPLICATION.pptx
 
Design and evaluation of bioequivalence
Design and evaluation of bioequivalenceDesign and evaluation of bioequivalence
Design and evaluation of bioequivalence
 
Electrosomes preparation and application
Electrosomes preparation and applicationElectrosomes preparation and application
Electrosomes preparation and application
 
Bioequivalence studies ( Evaluation and Study design)
Bioequivalence studies ( Evaluation and Study design)Bioequivalence studies ( Evaluation and Study design)
Bioequivalence studies ( Evaluation and Study design)
 
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
Biopharmaceutic considerations in drug product design and In Vitro Drug Produ...
 
Computer simulations in pharmacokinetics and pharmacodynamics
Computer simulations in pharmacokinetics and pharmacodynamicsComputer simulations in pharmacokinetics and pharmacodynamics
Computer simulations in pharmacokinetics and pharmacodynamics
 
Computers in Pharmaceutical formulation
Computers in Pharmaceutical formulationComputers in Pharmaceutical formulation
Computers in Pharmaceutical formulation
 
REGULATORY AND INDUSTRY VIEWS ON QbD, SCIENTIFICALLY BASED QbD- EXAMPLES OF A...
REGULATORY AND INDUSTRY VIEWS ON QbD, SCIENTIFICALLY BASED QbD- EXAMPLES OF A...REGULATORY AND INDUSTRY VIEWS ON QbD, SCIENTIFICALLY BASED QbD- EXAMPLES OF A...
REGULATORY AND INDUSTRY VIEWS ON QbD, SCIENTIFICALLY BASED QbD- EXAMPLES OF A...
 
Targeted drug delivery system
Targeted drug delivery systemTargeted drug delivery system
Targeted drug delivery system
 
alternative methods for dissolution.pptx
alternative methods for dissolution.pptxalternative methods for dissolution.pptx
alternative methods for dissolution.pptx
 
Pharmacokinetics and pharmacodynamics of biotechnological products
Pharmacokinetics  and  pharmacodynamics  of  biotechnological  productsPharmacokinetics  and  pharmacodynamics  of  biotechnological  products
Pharmacokinetics and pharmacodynamics of biotechnological products
 
Problems of variable
Problems of variableProblems of variable
Problems of variable
 
Compendial methods of dissolution testing
Compendial methods of dissolution testing Compendial methods of dissolution testing
Compendial methods of dissolution testing
 
Quality-by-Design in Pharmaceutical Development
Quality-by-Design in Pharmaceutical Development Quality-by-Design in Pharmaceutical Development
Quality-by-Design in Pharmaceutical Development
 
DESCRIPTIVE VERSUS MECHANISTIC MODELING ppt..pptx
DESCRIPTIVE VERSUS MECHANISTIC MODELING ppt..pptxDESCRIPTIVE VERSUS MECHANISTIC MODELING ppt..pptx
DESCRIPTIVE VERSUS MECHANISTIC MODELING ppt..pptx
 
Generic biologics.pptx
Generic biologics.pptxGeneric biologics.pptx
Generic biologics.pptx
 
Active transport
Active transportActive transport
Active transport
 

Similar to Drug interaction

drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdf
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdfdrugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdf
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdfVaibhavwagh48
 
Protein drug binding
Protein drug bindingProtein drug binding
Protein drug bindingSnehal Patel
 
12 Drug Distribution part 2
12 Drug Distribution part 212 Drug Distribution part 2
12 Drug Distribution part 2Nilesh Kulkarni
 
Protein drug binding.ppt
Protein drug binding.pptProtein drug binding.ppt
Protein drug binding.pptram choure
 
Protein Binding of Drugs by Dr. Sanaullah Aslam
Protein Binding of Drugs by Dr. Sanaullah AslamProtein Binding of Drugs by Dr. Sanaullah Aslam
Protein Binding of Drugs by Dr. Sanaullah AslamSanaullah Aslam
 
Drug interaction at plasma and tissue binding site
Drug interaction at plasma and tissue binding siteDrug interaction at plasma and tissue binding site
Drug interaction at plasma and tissue binding siteArabinda Changmai
 
Protein-Drug Interaction
Protein-Drug Interaction Protein-Drug Interaction
Protein-Drug Interaction Halavath Ramesh
 
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)Priyansha Singh
 
Protein binding of drugs
Protein binding of drugsProtein binding of drugs
Protein binding of drugsNaresh Gorantla
 
Pharmacokinetics Drug drug interaction [Best one]
Pharmacokinetics Drug drug interaction [Best one]Pharmacokinetics Drug drug interaction [Best one]
Pharmacokinetics Drug drug interaction [Best one]abdelrahman_asar
 

Similar to Drug interaction (20)

drug interaction
drug interactiondrug interaction
drug interaction
 
Drug intreaction
Drug intreactionDrug intreaction
Drug intreaction
 
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdf
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdfdrugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdf
drugintreaction-210802120hhhhhhhhhhhhhhh814 (1).pdf
 
Biopharma
BiopharmaBiopharma
Biopharma
 
Effects of Protein Binding
Effects of Protein Binding Effects of Protein Binding
Effects of Protein Binding
 
Protein binding
Protein bindingProtein binding
Protein binding
 
Protein drug binding
Protein drug bindingProtein drug binding
Protein drug binding
 
12 Drug Distribution part 2
12 Drug Distribution part 212 Drug Distribution part 2
12 Drug Distribution part 2
 
Protein binding of drugs
Protein binding of drugsProtein binding of drugs
Protein binding of drugs
 
Protein drug binding.ppt
Protein drug binding.pptProtein drug binding.ppt
Protein drug binding.ppt
 
bf
bfbf
bf
 
Drug interactions
Drug interactionsDrug interactions
Drug interactions
 
Protein Binding of Drugs by Dr. Sanaullah Aslam
Protein Binding of Drugs by Dr. Sanaullah AslamProtein Binding of Drugs by Dr. Sanaullah Aslam
Protein Binding of Drugs by Dr. Sanaullah Aslam
 
Drug interaction at plasma and tissue binding site
Drug interaction at plasma and tissue binding siteDrug interaction at plasma and tissue binding site
Drug interaction at plasma and tissue binding site
 
Protein-Drug Interaction
Protein-Drug Interaction Protein-Drug Interaction
Protein-Drug Interaction
 
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)
Protein binding unit 4 bppk pe 520 (final) [autosaved] (1)
 
Protein binding
Protein bindingProtein binding
Protein binding
 
Protein binding of drugs
Protein binding of drugsProtein binding of drugs
Protein binding of drugs
 
Drug interaction
Drug interactionDrug interaction
Drug interaction
 
Pharmacokinetics Drug drug interaction [Best one]
Pharmacokinetics Drug drug interaction [Best one]Pharmacokinetics Drug drug interaction [Best one]
Pharmacokinetics Drug drug interaction [Best one]
 

More from Manish Rajput

Thin layer chromatography. (TLC)
Thin layer chromatography. (TLC)Thin layer chromatography. (TLC)
Thin layer chromatography. (TLC)Manish Rajput
 
Characterization of Nanoparticles.
Characterization of Nanoparticles.Characterization of Nanoparticles.
Characterization of Nanoparticles.Manish Rajput
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)Manish Rajput
 
Buccal drug delivery system.
Buccal drug delivery system.Buccal drug delivery system.
Buccal drug delivery system.Manish Rajput
 
Regulatory provision related to manufacture of cosmetic
Regulatory provision related to manufacture of cosmeticRegulatory provision related to manufacture of cosmetic
Regulatory provision related to manufacture of cosmeticManish Rajput
 
Quality by design in pharmaceutical development
Quality by design in pharmaceutical developmentQuality by design in pharmaceutical development
Quality by design in pharmaceutical developmentManish Rajput
 

More from Manish Rajput (6)

Thin layer chromatography. (TLC)
Thin layer chromatography. (TLC)Thin layer chromatography. (TLC)
Thin layer chromatography. (TLC)
 
Characterization of Nanoparticles.
Characterization of Nanoparticles.Characterization of Nanoparticles.
Characterization of Nanoparticles.
 
Investigational new drug (IND)
Investigational new drug (IND)Investigational new drug (IND)
Investigational new drug (IND)
 
Buccal drug delivery system.
Buccal drug delivery system.Buccal drug delivery system.
Buccal drug delivery system.
 
Regulatory provision related to manufacture of cosmetic
Regulatory provision related to manufacture of cosmeticRegulatory provision related to manufacture of cosmetic
Regulatory provision related to manufacture of cosmetic
 
Quality by design in pharmaceutical development
Quality by design in pharmaceutical developmentQuality by design in pharmaceutical development
Quality by design in pharmaceutical development
 

Recently uploaded

Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxVishalSingh1417
 
Magic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptxMagic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptxdhanalakshmis0310
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
Third Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxThird Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxAmita Gupta
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Association for Project Management
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxheathfieldcps1
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseAnaAcapella
 
Dyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxDyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxcallscotland1987
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfNirmal Dwivedi
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...christianmathematics
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...pradhanghanshyam7136
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxnegromaestrong
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxVishalSingh1417
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...Nguyen Thanh Tu Collection
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.christianmathematics
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxRamakrishna Reddy Bijjam
 

Recently uploaded (20)

Unit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptxUnit-V; Pricing (Pharma Marketing Management).pptx
Unit-V; Pricing (Pharma Marketing Management).pptx
 
Magic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptxMagic bus Group work1and 2 (Team 3).pptx
Magic bus Group work1and 2 (Team 3).pptx
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Third Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptxThird Battle of Panipat detailed notes.pptx
Third Battle of Panipat detailed notes.pptx
 
Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...Making communications land - Are they received and understood as intended? we...
Making communications land - Are they received and understood as intended? we...
 
The basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptxThe basics of sentences session 3pptx.pptx
The basics of sentences session 3pptx.pptx
 
Spatium Project Simulation student brief
Spatium Project Simulation student briefSpatium Project Simulation student brief
Spatium Project Simulation student brief
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Spellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please PractiseSpellings Wk 3 English CAPS CARES Please Practise
Spellings Wk 3 English CAPS CARES Please Practise
 
Dyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptxDyslexia AI Workshop for Slideshare.pptx
Dyslexia AI Workshop for Slideshare.pptx
 
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdfUGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
UGC NET Paper 1 Mathematical Reasoning & Aptitude.pdf
 
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
Explore beautiful and ugly buildings. Mathematics helps us create beautiful d...
 
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...Kodo Millet  PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
Kodo Millet PPT made by Ghanshyam bairwa college of Agriculture kumher bhara...
 
Seal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptxSeal of Good Local Governance (SGLG) 2024Final.pptx
Seal of Good Local Governance (SGLG) 2024Final.pptx
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
TỔNG ÔN TẬP THI VÀO LỚP 10 MÔN TIẾNG ANH NĂM HỌC 2023 - 2024 CÓ ĐÁP ÁN (NGỮ Â...
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.This PowerPoint helps students to consider the concept of infinity.
This PowerPoint helps students to consider the concept of infinity.
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 

Drug interaction

  • 1. Faculty of Pharmacy, BBDNIIT Lucknow Drug Interaction Presented by- Manish Kumar Singh M.Pharm, I Year (Pharmaceutics) Presented to- Ms. Shipra Tripathi Assistant Professor
  • 2. Content  Pharmacokinetic  Drug interaction  Factor contributing to drug interactions  Protein binding of drug  Effect of protein binding interaction  Effect of tissue binding interaction
  • 3. Pharmacokinetics  Pharmacokinetics is a study of what the body does to drug.  It is a science of kinetics of ADME.  It is also defined as movement of drug in the body.  Elimination occur by two processes- Metabolism and Excretion.
  • 4. Drug Interactions  When the pharmacological activity of a drug is altered by the concomitant use of another drug or by the presence of some other substance.  The drug whose activity is affected by such an interaction is called as the object drug.  The agent which precipitates such an interaction is referred to as the precipitant. Drug interactions include 1. Drug-drug interactions. 2. Food-drug interactions, for example, inhibition of metabolism of several drugs by grapefruit juice. 3. Chemical-drug interactions, for example, interaction of a drug with alcohol, tobacco or environmental chemicals. 4. Drug-laboratory test interaction, for example, alteration of diagnostic laboratory test results by the presence of drug. 5. Drug-disease interactions, for example, worsening of disease condition by the drug.
  • 5. Factors Contributing to Drug Interactions Some of the more important risk factors that lead to drug interactions include – 1. Multiple drug therapy 2. Multiple prescribers 3. Multiple pharmacological effects of drug 4. Multiple diseases/Predisposing illness 5. Poor patient compliance 6. Advancing age of patient 7. Drug related factors
  • 6. Protein binding of drug The phenomenon of complex formation with proteins is called as protein binding of drugs. The formation of a drug–protein complex is often named drug–protein binding. The drug protein binding may be of two types- Reversible- When the drug bind the protein with weaker chemical bonds such as hydrogen bond or vander waal’s forces. Irreversible- Irreversible drug protein binding is usually a result of chemical activation of the drugs, which then attaches strongly to the protein or macromolecules by covalent chemical bonding.
  • 7. BINDING OF DRUGS TO BLOOD COMPONENTS  Albumin  Alpha 1- Acid Glycoprotein  Lipoprotein  Erythrocytes (RBC)  Immunoglobulins The extent or order of binding of drugs to various plasma proteins is: Abumin > alpha1-Acid Glycoprotein > Lipoproteins > Globulins
  • 8. Effect of protein binding interactions Apparent volume of distribution : It is defined as the hypothetical volume of body fluid into which a drug is dissolved or distributed. It is called as apparent volume because all parts of the body equilibrated with the drug do not have equal concentration. Effect Of Protein Binding On The Apparent Volume Of Distribution :  The extent of drug protein binding affects VD.  Drugs that are highly bound to plasma proteins have a low fraction of free drug (fu = unbound or free drug fraction).  The plasma protein-bound drug does not diffuse easily and is therefore less extensively distributed to tissues Apparent volume of distribution = Amount of the drug in the body Plasma drug concentration
  • 9.  Drugs with low plasma protein binding have larger fu, generally diffuse more easily into tissues, and have a greater volume of distribution.  Drugs such as furosemide, sulfisoxazole, tolbutamide, and warfarin are bound greater than 90% to plasma proteins and have a VD value ranging from 7.7 to 11.2 L per 70-kg body weight.  Basic drugs such as imipramine, nortriptyline, and propranolol are extensively bound to both tissue and plasma proteins and have very large VD values. Displacement of drugs from plasma proteins can affect the pharmacokinetics of a drug in several ways : directly increase the free (unbound) drug concentration as a result - 1. Reduced binding in the blood; 2. Reaches the receptor sites directly, causing a more intense pharmacodynamic (or toxic) response; 3. Causing a transient increase in VD and decreasing partly some of the increase in free plasma drug concentration; 4. More drug diffusion into tissues of eliminating organs, particularly the liver and kidney, resulting in a transient increase in drug elimination.
  • 10. Effect Of Protein Binding On Elimination Of Drug :  Protein binding decreases the renal excretion of the drugs and enhance the biological half –life. Only the free drugs excreted through filtration for example tetracycline.  The binding of drugs in extravascular organs decreases their concentration in blood and thereby shows their elimination by liver, kidney and lungs.  However, the binding of drug to plasma protein may retard the elimination of drugs depending on the mechanism of elimination, for example the binding of drug to the plasma protein lowers their unbound concentration in blood and thereby decreases their rate of elimination by glomerular filtration and by inefficient transport system in the kidney.  Binding to plasma protein would decreases the rate of elimination of lipid soluble drugs that diffuse rapidly from the glomerular filtration back into the blood, even though they are rapidly transported by active transport system.  In addition, the binding of drug to plasma protein would also decreases the rate of drug metabolism by relatively inactive enzyme system in liver.
  • 11. Effect Of Protein Binding On Patient With Kidney Disease :  Albumin is primarily responsible for the binding of acidic drugs whereas basic drugs appear to bind preferentially to AAG (alpha-amino glycoprotein).  The low concentration of albumin and AAG in patients with liver disease indicates the inability of the liver to synthesize these drug-binding proteins.  Impaired binding of acidic and basic drugs is well documented in patients with liver disease.  The albumin concentrations in the transplant patients were low despite stable biochemical liver tests. Because albumin is primarily responsible for binding of acidic drugs, liver transplant patients would not be able to bind acidic drugs as efficiently as the normal subjects.  However, the AAG concentrations were elevated in all the transplant patients studied. AAG is an acute-phase reactant and is primarily synthesized in the liver.  AAG concentrations are known to increase in plasma.
  • 12. Effect Of Protein Binding On Patients With Hepatic Disease :  Protein binding affects distribution.  The impaired liver is unable to synthesize plasma proteins (albumin) adequately.  Liver impairment causes accumulation of substances (bilirubin) that displace drugs from protein-binding sites.  A statistics on this case shows that liver disease patients with normal concentration of albumin and bilirubin have unbound percentages of frusemide similar to those in healthy subjects.
  • 13. Effect of tissue binding interactions TISSUE BINDING OF DRUGS (TISSUE LOCALIZATION OF DRUGS) A drug can bind to one or more of the several tissue components. Tissue-drug binding is important in distribution from two viewpoints :  It increases the apparent volume of distribution of drugs in contrast to plasma protein binding which decreases it.  Tissue-drug binding results in localization of a drug at a specific site in the body (with a subsequent increase in biological half-life). This is more so because a number of drugs bind irreversibly with the tissues (contrast to plasma protein-drug binding); for example, oxidation products of paracetamol, phenacetin, chloroform, carbon tetrachloride and bromobenzene bind covalently to hepatic tissues.
  • 14. Factors influencing localization of drugs in tissues include : 1. lipophilicity and structural features of the drug, 2. perfusion rate, 3. pH differences, etc. Extensive tissue-drug binding suggests that a tissue can act as the storage site for drugs. Drugs that bind to both tissue and plasma components result in competition between drug binding sites. For majority of drugs that bind to extravascular tissues, the order of binding is: Liver > Kidney > Lung > Muscles
  • 15. Several Examples Of Extravascular Tissue-drug Binding Are 1. Liver: Paracetamol bind irreversibly to liver tissues resulting in hepatotoxicity. 2. Lungs: Basic drugs like imipramine, chlorpromazine and antihistamines accumulate in lungs. 3. Kidneys: Metallothionin, a protein present in kidneys, binds to heavy metals such as lead, mercury, and cadmium and results in their renal accumulation and toxicity. 4. Skin: Chloroquine and phenothiazines accumulate in skin by interacting with melanin. 5. Eyes: The retinal pigments of the eye also contain melanin. Binding of chloroquine and phenothiazines to it is responsible for retinopathy. 6. Hairs: Arsenicals, chloroquine and phenothiazines are reported to deposit in hair shafts.
  • 16. 7. Bones: Tetracycline is a well-known example of a drug that binds to bones and teeth. Administration of this antibiotic to infants or children during odontogenesis results in permanent brown-yellow discoloration of teeth. 8. Fats: Lipophilic drugs such as thiopental and the pesticide DDT accumulate in adipose tissues by partitioning into it. 9. Nucleic Acids: Molecular components of cells such as DNA interact strongly with drugs like chloroquine and quinacrine resulting in distortion of its double helical structure.
  • 17. References  Shargel L. ,” Applied Biopharmaceutics & Pharmacokinetics”, 7th Edition, 2005, Published by McGraw Hill, New York, Page no – 267,276,277.  Brahmankar D.M. , Jaiswal S.B. , “Biopharmaceutics and Pharmacokinetics- A Treatise”, 1995, Published by Vallabh Prakashan, New Delhi, Page no- 116-123.  https://www.slideshare.net/azamushahiullahprottoy/effects-of-protein- binding